These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6977906)

  • 41. [Immunity in Hodgkin's lymphoma].
    Danieli G; Montroni M; Leoni P; Magelli L; Totti S
    G Clin Med; 1975; 56(1):39-56. PubMed ID: 770222
    [No Abstract]   [Full Text] [Related]  

  • 42. Lack of correlation between skin reactivity and T lymphocytes and monocytes in Hodgkin's disease.
    Müftüoğlu AU; Yalçin B
    Acta Haematol; 1980; 63(5):286-8. PubMed ID: 6774558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lymphoid subpopulations of peripheral blood and spleen in untreated Hodgkin's disease.
    Posner MR; Reinherz EL; Breard J; Nadler LM; Rosenthal DS; Schlossman SF
    Cancer; 1981 Sep; 48(5):1170-6. PubMed ID: 6456062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantitation of immunocompetence in Hodgkin's disease.
    Faguet GB
    J Clin Invest; 1975 Oct; 56(4):951-7. PubMed ID: 1159096
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphocyte subpopulations in Hodgkin's disease and non-Hodgkin's lymphoma and the effects of radiotherapy.
    Balasem AN; Barker CR
    Clin Radiol; 1984 Sep; 35(5):353-7. PubMed ID: 6236011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.
    Land JM; Litwin J; Bigel P; Oberling F; Mayer S
    Acta Haematol Pol; 1977; 8(2):131-4. PubMed ID: 329629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cellular immunity in patients with Hodgkin's disease: modification induced by incubating lymphocytes with fetal calf serum and Hodgkin's serum].
    Rambotti P; Velardi A; Spinozzi F; Falini B; Martelli MF
    Boll Ist Sieroter Milan; 1979 Mar; 58(1):90-9. PubMed ID: 552840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunological monitoring during chemotherapy for advanced Hodgkin's disease.
    Alexopoulos CG; Wiltshaw E
    Cancer; 1978 Dec; 42(6):2631-40. PubMed ID: 310334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of radiochemotherapy and splenectomy on lymphoid subclasses in patients with Hodgkin's lymphoma in complete remission].
    Leoni P; Montroni M; Montillo M; Salvi A; Centurioni R; Fanciulli E
    G Clin Med; 1981 Oct; 62(10):685-92. PubMed ID: 6977469
    [No Abstract]   [Full Text] [Related]  

  • 50. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Pathol Biol (Paris); 1978; 26(3-4):159-62. PubMed ID: 355984
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
    Lang JM; Bigel P; Oberling F; Mayer S
    Sem Hop; 1978 Nov 8-15; 54(37-40):1155-8. PubMed ID: 217096
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunologic study on nasopharyngeal carcinoma patients: correlation of in vivo and in vitro reactivity to phytohemagglutinin.
    Hsu MM; Lo P
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1983 Feb; 16(1):20-32. PubMed ID: 6851721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Immunological aspects of Hodgkin's disease].
    Bianchini E
    Minerva Med; 1975 Feb; 66(8):365-70. PubMed ID: 1078722
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin's lymphomas.
    Schreiber DP; Jacobs C; Rosenberg SA; Cox RS; Hoppe RT
    Int J Radiat Oncol Biol Phys; 1985 Jan; 11(1):31-6. PubMed ID: 3838166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tissue T-lymphocytes in untreated Hodgkin's disease: morphologic and functional correlations in spleens and lymph nodes.
    Baroni CD; Ruco L; Uccini S; Foschi A; Occhionero M; Marcorelli E
    Cancer; 1982 Jul; 50(2):259-68. PubMed ID: 6979382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evidence for the involvement of monocyte-derived toxic oxygen metabolites in the lymphocyte dysfunction of Hodgkin's disease.
    Deshazo RD; Ewel C; Londono S; Metzger Z; Hoffeld JT; Oppenheim JJ
    Clin Exp Immunol; 1981 Nov; 46(2):313-20. PubMed ID: 7337972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Depressed in vitro lymphocyte responses to PHA in patients with Hodgkin disease in continuous long remissions.
    Case DC; Hansen JA; Corrales E; Young CW; Dupont B; Pinsky CM; Good RA
    Blood; 1977 May; 49(5):771-8. PubMed ID: 322770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zinc and anergy in pediatric Hodgkin's disease in Turkey.
    Cavdar AO; Babacan E; Gözdaşoğlu S; Erten J; Cin S; Arcasoy A; Ertem U
    Cancer; 1987 Jan; 59(2):305-9. PubMed ID: 3802017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunological defects in healthy twin siblings to patients with Hodgkin's disease.
    Björkholm M; Holm G; De Faire U; Mellsted H
    Scand J Haematol; 1977 Oct; 19(4):396-404. PubMed ID: 562530
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunity in Hodgkin's disease: status after 5 years' remission.
    Hancock BW; Bruce L; Whitham MD; Dunsmore IR; Ward AM; Richmond J
    Br J Cancer; 1982 Oct; 46(4):593-600. PubMed ID: 7138765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.